Endocrine Abstracts

Introduction: Radioiodine (131I, RAI) is a safe and effective option for the treatment of Graves’ disease (GD). However, approximately 20% of RAI treated patients will have persistent disease or will relapse after the first treatment. Our aim was to identify the factors influencing the outcomes in RAI treatment for GD.Methods: We analysed 143 DG patients (116 women) treated with RAI between October 2002 and April 2014 and ≥12 months...